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Article focus
  The purpose of this study was to charac-
terize rifampin-loaded poly(methyl meth-
acrylate) (PMMA) bone cement.
  The cause of chemical incompatibility 
between rifampin and the cement was 
investigated, and various clinically rele-
vant properties of the rifampin-loaded 
cement were determined.
  Surgical contraindications of rifampin-
loaded PMMA bone cement were 
identified.
Key messages
  The addition of rifampin to PMMA bone 
cement interferes with the radical polym-
erization mechanism, resulting in delayed 
cement curing and reduced compressive 
strength.
  The hydroquinone structure within 
rifampin acts as a radical scavenger.
  The resulting incomplete polymerization 
of the cement causes unreacted toxic 
monomer to leach from the cement over 
time.
Radical scavenging of poly(methyl 
methacrylate) bone cement by rifampin 
and clinically relevant properties of the 
rifampin-loaded cement
Objectives
The objective of this study was to characterize the effect of rifampin incorporation into 
poly(methyl methacrylate) (pMMA) bone cement. While incompatibilities between the 
two materials have been previously noted, we sought to identify and quantify the cause 
of rifampin’s effects, including alterations in curing properties, mechanical strength, and 
residual monomer content.
Methods
Four cement groups were prepared using commercial pMMA bone cement: a control; one 
with 1 g of rifampin; and one each with equimolar amounts of ascorbic acid or hydroquinone 
relative to the amount of rifampin added. The handling properties, setting time, exothermic 
output, and monomer loss were measured throughout curing. The mechanical strength of 
each group was tested over 14 days. A radical scavenging assay was used to assess the scav-
enging abilities of rifampin and its individual moieties.
Results
compared with control, the rifampin-incorporated cement had a prolonged setting time 
and a reduction in exothermic output during polymerization. The rifampin cement showed 
significantly reduced strength and was below the orthopaedic weight-bearing threshold of 
70 Mpa. Based on the radical scavenging assay and strength tests, the hydroquinone struc-
ture within rifampin was identified as the polymerization inhibitor.
Conclusion
The incorporation of rifampin into pMMA bone cement interferes with the cement’s radical 
polymerization. This interference is due to the hydroquinone moiety within rifampin. This 
combination alters the cement’s handling and curing properties, and lowers the strength 
below the threshold for weight-bearing applications. Additionally, the incomplete polym-
erization leads to increased toxic monomer output, which discourages its use even in non-
weight-bearing applications.
cite this article: Bone Joint Res 2019;8:81–89.
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strengths and limitations
  A multitude of tests were performed to give a full 
characterization of rifampin-loaded PMMA bone 
cement.
  Compressive properties of, and unreacted monomer 
loss from, the cement may vary in vivo.
introduction
Infection associated with orthopaedic surgery, and more 
specifically total joint arthroplasty (TJA), is a severe com-
plication to patients and burdens the healthcare system.1 
While prosthetic joint infection (PJI) occurs in only 1% to 
3% of TJA cases, the associated costs to the United States 
healthcare system are projected to be US$1.62 billion by 
the year 2020.2-4 Poly(methyl methacrylate) (PMMA) is 
the major component of commercially available ortho-
paedic bone cement. It is used to anchor the implant in 
the bone during primary cases, and in fabricating weight-
bearing spacers during revision surgery. Bone cement is 
routinely loaded with antibiotic(s), both prophylactically 
and as part of infected revision as a means of delivering 
high local doses of antibiotics, while avoiding the sys-
temic toxicity associated with intravenous administra-
tion.5,6 Staphylococcus aureus (S. aureus) and 
coagulase-negative Staphylococcus spp. are the most 
prevalent infectious organisms following orthopaedic 
surgery.7 Therefore, glycopeptide antibiotics such as van-
comycin, and aminoglycosides such as gentamicin, are 
the most commonly incorporated drugs to treat PJI.8-10
often, PJI will result in the formation of a biofilm on or 
near the implant. A biofilm is a collection of bacteria that 
forms a protective barrier with innate resistance to antibi-
otics, and has a high propensity to develop on inert sur-
faces such as implants and post-surgical bone.11,12 The 
presence of these biofilms can make standard antibiotic 
treatments ineffective, as both vancomycin and gen-
tamicin are ineffective at clearing biofilms.13 Unlike van-
comycin and gentamicin, rifampin is highly effective 
against staphylococcal biofilms.13,14 Rifampin is used sys-
temically in nearly all orthopaedic infection treatment 
regimens, especially when the presence of methicillin-
resistant S. aureus (MRSA) is suspected.15 Even at easily 
achievable infection site concentrations of 1 μg/ml to 
8 μg/ml, rifampin can lead to a 5 log10 to 9 log10 reduc-
tion in bacterial biofilms and suppress bacterial recovery 
by up to 24 hours post-treatment, which indicates almost 
complete eradication of the biofilm.16
Recently, there has been increased interest in charac-
terizing the ability of PMMA bone cement to act as a car-
rier for local delivery of rifampin to fight infection in the 
presence of biofilms.16-18 In this regard, a number of 
adverse effects associated with rifampin-loaded PMMA 
bone cement have been reported.17,19 Rifampin, which 
was approved in the United States in 1971, was recog-
nized early on as having a detrimental effect on PMMA 
polymerization and strength, and, as a result, has long 
been discounted as a possible additive to bone cement. 
Although clearly recognized, the cause of rifampin’s 
incompatibility has never been experimentally deter-
mined, nor has the effect been quantified.
An understanding of possible mechanisms for the 
effect of rifampin on PMMA bone cement may be 
obtained by analyzing the chemical structure and prop-
erties of the antibiotic. Rifampin contains both a hydro-
quinone and piperazine moiety within its structure 
(Fig. 1). Both are known radical scavengers. The ability of 
rifampin to act as a radical scavenger was noted previ-
ously by Tomiyama et al20 in a 1996 study, where they 
used rifampin to inhibit β protein aggregation in an 
Alzheimer’s model. Pozdeeva and Denisov21 investigated 
the mechanism of hydroquinone-mediated oxidation of 
methyl methacrylate (MMA), and determined its impact 
on slowing the rate of the reaction. Aware of the scaveng-
ing potential of rifampin, McPherson and Portugal19 pro-
posed that rifampin reacted with the cement’s initiators 
to quench the polymerization process. They reported 
increases in cement curing time, but this work was a case 
study and mechanical properties were not determined.
little experimental work has been performed to under-
stand and overcome rifampin’s effect on PMMA. one 
paper by Rose et  al18 evaluated rifampin release from 
poly(styrene-co-MMA monomer) (PS-PMMA) films rather 
than from PMMA bone cement itself. In two separate stud-
ies by Sanchez et al16 and Shiels et  al,17 the elution and 
effectiveness of rifampin-loaded PMMA bone cement 
beads using in vitro bioassays16 and in a rat infection 
model17 were investigated. While the investigators found 
reasonable antibacterial effectiveness, they also remarked 
on the slow and incomplete curing of the cement. low 
strength and stiffness of rifampin-loaded cement remain 
major shortcomings for weight-bearing applications. In 
the referenced studies, the mechanism of rifampin’s chem-
ical interaction with the cement was not investigated.
The purpose of the present study was to elucidate the 
interaction between rifampin and a commercially availa-
ble PMMA bone cement, and to determine a number of 
clinically relevant properties of the composite material. 
These characteristics include its biomechanical strength 
and modulus over time, surface morphology, curing 
time, and the amount of unreacted monomer still pre-
sent within the cement. Additionally, we sought to utilize 
a radical scavenging assay to verify experimentally the 
mechanism of interaction between rifampin and the 
cement. We hypothesized that the hydroquinone unit 
contained within rifampin acts as a radical scavenger, 
and is responsible for the interaction of rifampin with the 
cement’s polymerization process. Two known radical 
scavenging molecules, ascorbic acid and hydroquinone, 
were also added to PMMA bone cement to further illus-
trate and verify this chemical interaction.
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Materials and Methods
Materials. The PMMA bone cement brand used was 
SmartSet Mv (DePuy Synthes, Blackpool, United 
Kingdom). The cement was sterile and used before its 
expiration date. Four groups of cement were prepared: 
a negative control without any additive (CoN); one 
loaded with 1 g of rifampin (RIF); and two positive con-
trols loaded with either ascorbic acid (AA) or hydroqui-
none (HQ). In the RIF, AA, and HQ groups, the mass of 
the additive was selected so that the molar amount was 
the same (Table I).
A low dosage of rifampin (1 g) was chosen to differ-
entiate between a ‘filler’ and ‘chemical’ interaction. 
Hydroquinone and ascorbic acid were chosen based 
upon their known functions as radical scavengers.21,22 
Furthermore, it is to be noted that in many commer-
cially available PMMA bone cement brands (including 
SmartSet Mv), hydroquinone is a constituent of the liq-
uid component and serves to stabilize the polymeriza-
tion reaction.23
Determination of curing properties. First, the additives 
were mixed with the 40 g dry cement component, after 
which the liquid monomer was added, and the material 
was blended in a polymeric bowl that was open to the 
ambient laboratory atmosphere. After initial mixing of 
the cement, dough time (td) was determined as the time 
at which the dough was probed without adherence, serv-
ing as the first checkpoint towards polymerization. An ali-
quot (10 g) from each group was removed and placed 
within a polytetrafluoroethylene (PTFE) thermocouple 
mould based on the ASTM International standard speci-
fication for acrylic bone cement, ASTM F451-16.24 The 
internal temperature of each group was recorded every 
five seconds throughout curing using K-type thermocou-
ple wires, along with oM-Pl series data logger software 
(oMEGA Engineering, Inc., Stamford, Connecticut). The 
setting time (tset) of each cement group was calculated by 
exothermic output, numerically the corresponding time 
at which the internal temperature was equal to half the 
sum of the maximum temperature and ambient tempera-
ture: tset = (Tmax + Tambient)/2.
Determination of compressive properties. The remain-
der of the cement dough that was not used in the deter-
mination of curing properties was pressed into a PTFE 
cylindrical mould and allowed to cure at 37°C for one 
hour, producing specimens with a diameter and height 
of 6 mm and 12 mm, respectively.24 The specimens 
were then inspected visually for defects. A total of 30 
specimens without defects were selected randomly and 
placed into individual 15 ml vials. of the 30 specimens, 
20 were immersed in 2.5 ml of 1 × phosphate-buffered 



















The chemical structure of rifampin. The hydroquinone (1) and piperazine (2) moieties have been labelled.
table i. Cement group composition and study role
Cement group Additive Amount, g (mol) Purpose
CoN None N/A Negative control
RIF Rifampin 1.00 (1.2 × 10-3) Experimental
AA Ascorbic acid 0.21 (1.2 × 10-3) Positive control
HQ Hydroquinone 0.13 (1.2 × 10-3) Positive control
CoN, negative control without any additive; N/A, not applicable; RIF, loaded with 1 g of rifampin; AA, positive control loaded with ascorbic acid; HQ, positive 
control loaded with hydroquinone
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the solution refreshed every 24 hours. The remaining ten 
were kept dry.
All compression testing was carried out in accordance 
with ASTM F451-16 to measure both compressive 
strength and modulus.24 Testing was performed using an 
MTS 858 Mini Bionix II hydraulic load frame (MTS Systems 
Corp., Eden Prairie, Minnesota). The dry specimens from 
each group were crushed 24 hours after curing, repre-
senting ‘Day 1’, while ten specimens from each group 
were tested after seven and 14 days of soaking.
Radical scavenging assay. α,α-Diphenyl-β-picrylhydrazyl 
(DPPH) is a molecule with a stabilized free radical, and 
is often used for testing the antioxidant (radical scav-
enging) potential of plant extracts and pharmaceuticals. 
Employed in an assay, it can be robust, highly reproduc-
ible, and usable with a wide range of antioxidant com-
pounds.25 The procedure we used was adapted from the 
study by Blois.26 Six analytes were used for this test: ascor-
bic acid; hydroquinone; rifampin; vancomycin (vANC); 
gentamicin (GENT); and 1-methylpiperazine (PIP). 
Gentamicin and vancomycin were chosen for compari-
son because they are antibiotics commonly and success-
fully incorporated into PMMA bone cement. Each analyte 
was incubated with DPPH in spectroscopy-grade metha-
nol (Thermo Fisher Scientific, Fair lawn, New Jersey) for 
30 minutes in the dark, and the absorption at 515 nm 
was measured. A loss of absorption at this wavelength 
indicated radical quenching of the DPPH by the ana-
lyte. The absorption of each was compared with a DPPH 
control solution of the same stock. The efficient concen-
tration value required to quench or reduce the control 
absorbance by 50%, EC50, was used to quantify the effect 
of the analyte as proposed by Bondet et al.27 Thus, the 
lower the EC50, the higher the radical scavenging potency 
of the analyte. Each analyte was tested in triplicate.
Cement surface morphology. A qualitative surface analy-
sis of both CoN and RIF cement pellets was performed 
via scanning electron microscopy (SEM). The CoN and 
RIF specimens were chosen to determine the influence 
of rifampin incorporation on the surface morphology 
of the cement. A single dry specimen from each group 
was sputter-coated with an 80:20 gold-palladium alloy. 
Images were taken with 100 × magnification using a 
scanning electron microscope (Hitachi S-2700; Hitachi, 
Tokyo, Japan) equipped with a Quartz PCI digital capture 
(Quartz Imaging Corporation, vancouver, Canada).
Volatile monomer weight loss quantification. In order to 
quantify the amount of volatile monomer leaching from 
the cement, fresh batches of both CoN and RIF cement 
were prepared. Each of these cements was mixed as 
before until td was reached, at which point the cement 
was spread throughout the bowl and placed on an 
enclosed pre-tared scale. The mass of each was recorded 
over the course of 24 hours.
statistical analysis. For each of the quantitative properties 
determined, the results are presented as ± 1 sd. Statistical 
analysis was performed using one-way analysis of variance 
(ANovA) and post hoc unpaired Student’s t-tests (Microsoft 
Excel; Microsoft, Redmond, Washington). Statistical differ-
ences were considered significant if p < 0.05.
Results
Curing properties. The td, tset, and Tmax of the cement 
achieved during curing for each cement group are listed in 
Table II. It is seen that td and tset of RIF are each significantly 
higher than the corresponding value for CoN. visually, a 
colour change from bright red to deep red-brown in RIF 
was observed during cement mixing. For RIF and HQ, a 
strong acrylic monomer scent was present and persistent 
throughout mixing and curing. Greater polymerization 
inhibition was observed in HQ. The AA showed no appre-
ciable changes in td or tset, indicating that ascorbic acid 
has no effect on the polymerization of the cement. The 
exothermic output log for each cement group is displayed 
in Figure 2. The CoN and AA exhibited similar exother-
mic outputs, both achieving Tmax > 90°C within minutes, 
while tailing off quickly. The RIF had a slow rise in exo-
thermic temperature (Tmax = 42.5°C) over the course of 45 
minutes, with slow dissipation thereafter. The HQ showed 
a minimal increase in temperature throughout curing.
Compressive properties. The compressive strengths of 
the cements are presented in Figure 3. Each group var-
ied significantly from CoN during each timepoint (p < 
0.05). The AA showed strength above 70 MPa (the mini-
mum required strength, per ASTM F451) throughout the 
testing period, and increased in strength significantly 
over the course of seven days. The RIF had significantly 
reduced strength when compared with CoN and stayed 
well below 70 MPa over the course of 14 days. The HQ 
exhibited minimal strength and remained elastic, even 
after 14 days.
The modulus for each composite group is shown in 
Figure 4. The moduli of CoN and AA were not signifi-
cantly different from one another over the course of 14 
days. The modulus of RIF was significantly lower than 
that of CoN over the course of 14 days. The HQ showed 
very low moduli over the course of 14 days.
Radical scavenging testing. The radical scavenging 
results for each analyte are presented in Figure 5. Both 
positive controls (AA and HQ) behaved as potent radical 
table ii. Pertinent handling and curing properties of each cement group 
as defined by the ASTM International standard specification for acrylic bone 
cement, ASTM F451-1624
Cement group td, mins tset, mins tmax, °C
CoN 3.50 7.25 92.5
RIF 4.50 33.00 42.5
AA 3.50 7.50 90.1
HQ 4.75 34.75 27.6
td, dough time; tset, setting time; Tmax, maximum temperature; CoN, 
negative control without any additive; RIF, loaded with 1 g of rifampin; AA, 
positive control loaded with ascorbic acid; HQ, positive control loaded with 
hydroquinone
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scavengers at low concentrations (EC50). likewise, RIF 
exhibited potent scavenging, although not quite as 
much as AA and HQ. The vANC and GENT were unreac-
tive towards the DPPH radical. 1-methylpiperazine, while 
known to function as a radical scavenger, did not show 
an appreciable effect at comparable concentrations.
surface morphologies. The results for CoN and RIF are dis-
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Fig. 2
line graph showing a sample curing temperature versus curing time profiles. CoN, negative control without any additive; RIF, loaded with 1 g of rifampin; AA, 























Chart summarizing the compressive strength values. An asterisk (*) denotes a significant difference from control, p < 0.05. The dashed line indicates the 70 MPa 
threshold. Ten specimens were tested from each group. CoN, negative control without any additive; RIF, loaded with 1 g of rifampin; AA, positive control loaded 
with ascorbic acid; HQ, positive control loaded with hydroquinone.
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of CoN appears to be solid without major pores and is 
generally homogeneous. Conversely, the surface of RIF is 
inconsistent and contains major structural defects in the 
form of deep pores and rifts.
Volatile monomer weight loss. The CoN and RIF cements 
lost 0.40 g and 2.42 g over 24 hours, respectively, rep-
resenting a 500% increased loss in volatile monomer 
from RIF. The CoN showed no appreciable weight loss 
after 20 minutes. The RIF weight loss continued over the 
course of 24 hours, revealing a steady release of mono-
mer (Supplementary Fig. a).
Discussion
The effect of rifampin on the polymerization of PMMA 
bone cement has been the subject of previous studies.17,19 
However, in these studies, only limited attention was 
given to both elucidating the mechanism involved in the 
interaction between the materials and determining 

















Chart summarizing the computed EC50 results. An asterisk (*) denotes a significant difference from rifampin (RIF). Three specimens were tested from each group. 




















Chart summarizing the compressive modulus values. An asterisk (*) denotes a significant difference from control, p < 0.05. Ten specimens were tested from 
each group. CoN, negative control without any additive; RIF, loaded with 1 g of rifampin; AA, positive control loaded with ascorbic acid; HQ, positive control 
loaded with hydroquinone.
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clinically relevant properties of the rifampin-loaded 
cement. These aspects are covered in the present work. 
Regarding the cement curing, td and tset of RIF were each 
significantly higher than the corresponding value for 
CoN. over the course of 14 days, the compressive 
strength of RIF was significantly lower than that of CoN. 
The reduction both in compressive strength and modu-
lus from the addition of 1 g of rifampin to the cement is 
not merely an artefact of the space occupied by the anti-
biotic, as this reduction is not seen with similar loading of 
other antibiotics.28,29 Hydroquinone and rifampin gave 
similarly low EC50 values, representing potent radical 
scavenging activity. Thus, the hydroquinone moiety 
within rifampin acts as a radical scavenger during PMMA 
polymerization. It is directly responsible for the pro-
longed curing time, reduced mechanical strength, and 
observed surface porosity of RIF stemming from incom-
plete cement polymerization. Furthermore, the effect of 
partial cement polymerization on toxic MMA release 
from RIF has not been quantified previously in the litera-
ture. our results show that, over the course of 24 hours, 
a substantial amount of MMA was released from the RIF 
specimen.
The addition of ascorbic acid had no appreciable 
adverse effect on the handling and curing properties of 
the cement with respect to control. Interestingly, the 
DPPH assay revealed a similar EC50 value for ascorbic acid 
compared with both hydroquinone and rifampin, high-
lighting its known nature as a potent radical scavenger. 
While AA and CoN showed similar curing properties, the 
compressive strength of AA was significantly lower but 
remained above 70 MPa. Investigation into this discrep-
ancy revealed solubility issues within the curing cement. 
Specifically, the high water solubility of the ascorbic acid 
could have limited its ability to quench the radical chain 
in the hydrophobic PMMA matrix.
The present study highlights the detrimental effects of 
incorporating rifampin into PMMA bone cement. 
Although the systemically administered combination 
therapy of rifampin and another antibiotic is common, 
rifampin is seldom used alone.14 Rifampin monotherapy 
has been linked to a high likelihood of the emergence of 
resistant pathogens, two of which are the most common 
orthopaedic infection-causative organisms: S. aureus and 
S. epidermis.30-32 While the incorporation of a second anti-
biotic, in addition to rifampin, into PMMA bone cement 
may alleviate some of the concerns of pathogen resist-
ance, the presence of rifampin may still cause the adverse 
effects on the cement presented in this study.
other studies have investigated ways to overcome the 
deleterious effects of rifampin incorporation in commer-
cial PMMA bone cement. one approach is the encapsula-
tion of rifampin before it is mixed with the cement. 
Sanz-Ruiz et  al33 encapsulated rifampin and reported 
effective elution of the antibiotic while preserving the 
mechanical properties of PMMA. Similar results were 
reported with the use of rifampin-filled cyclodextrin (CD) 
microparticles. Cyphert et al34 found that the inclusion of 
CD microparticles in PMMA resulted in similar mechani-
cal properties to the PMMA control and may serve as a 
refillable antibiotic delivery vehicle. While encapsulation 
of rifampin is a potential technique that may be used to 
include this drug in a commercial product, it is not cur-
rently an option for the orthopaedic surgeon in the oper-
ating theatre unless encapsulated rifampin is made 
available as a separate product. Additional investigations 
have included using alternative delivery vehicles, such as 
bioresorbable carriers like sponges and calcium sulphate, 
which utilize compositions other than PMMA and allevi-
ate the concern of polymerization inhibition.35,36 While 
these bioresorbable materials have the potential to 
release therapeutic levels of rifampin, they have often 
been limited to non-weight-bearing applications.
Fig. 6a
Fig. 6b
a) Morphology of the surface of CoN (negative control without any additive). 
Magnified ×100. 115 mm × 89 mm (96 × 96 DPI). b) Morphology of the sur-
face of RIF (loaded with 1 g of rifampin) specimen. Magnified ×100. 114 mm 
× 89 mm (96 × 96 DPI).
88 G. A. Funk, E. M. MEnuEy, k. A. ColE, T. P. SChuMAn, k. V. kilwAy, T. E. MCiFF
BonE & JoinT RESEARCh
In conclusion, the results of the present study demon-
strate that the hydroquinone moiety within rifampin inter-
feres with the polymerization of PMMA bone cement, 
resulting in significantly prolonged cement curing and 
setting times. This substantial delay represents a severe 
disadvantage to surgeons by increasing operating time 
and reducing the cement’s handleability.37 As a result, it 
impacts the healthcare economy negatively and results in 
a longer operating time, which is correlated with a higher 
risk of infection when involving invasive procedures such 
as joint arthroplasties.38-41 Additionally, compared with the 
cement without rifampin, the compressive strength and 
modulus of the rifampin-loaded cement are significantly 
lower, and the amount of unreacted monomer loss is sub-
stantially higher. The lattermost characteristic potentially 
poses a threat to the health of the patient and of the oper-
ating room staff. Toxic occupational exposure to MMA is 
scarce in orthopaedic literature but common in dental lit-
erature, where olfactory lesions and local tissue necrosis 
are reported.42 These findings suggest that the use of 
rifampin-incorporated PMMA bone cement in its current 
form should be discouraged for both weight-bearing and 
non-weight-bearing applications in orthopaedics.
supplementary Material
line graph quantifying the amount of volatile mon-
omer leaching from CoN (negative control without 
any additive) and RIF (loaded with 1 g of rifampin) 
cements over the course of 24 hours.
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